Winston Churchill Biography and Net Worth

Director of Baudax Bio


Winston J. Churchill has been a director of the Company since 2019. He has been a director of the Recro Pharma since 2008. Since 2007, Mr. Churchill has been a director of the corporate general partner of the common general partner of SCP Vitalife. He has also served as a managing member of SCP Vitalife Management Company, LLC, which by contract provides certain management services to the common general partner of SCP Vitalife. Mr. Churchill has also served since 1993 as the President of CIP Capital Management, Inc., the general partner of CIP Capital, L.P., an SBA-licensed private equity fund. Prior to that, Mr. Churchill was a managing partner of Bradford Associates, which managed private equity funds on behalf of Bessemer Securities Corporation and Bessemer Trust Company. From 1967 to 1983, Mr. Churchill practiced law at the Philadelphia firm of Saul Ewing, LLP, where he served as Chairman of the Banking and Financial Institutions Department, Chairman of the Finance Committee and was a member of the Executive Committee. Mr. Churchill is a director of Griffin Land & Nurseries, Inc., Innovative Solutions and Support, Inc., Amkor Technology, Inc. and various SCP Vitalife portfolio companies. In addition, he serves as a director on the boards of several charities and as a trustee of educational institutions including the Gesu School and Scholar Academies and is a Trustee Fellow of Fordham University. From 1989 to 1993, Mr. Churchill served as Chairman of the Finance Committee of the Pennsylvania Public School Employees’ Retirement System.

He was awarded a B.S. in Physics, summa cum laude, from Fordham University followed by an M.A. in Economics from Oxford University, where he studied as a Rhodes Scholar, and a J.D. from Yale Law School.

What is Winston J. Churchill's net worth?

The estimated net worth of Winston J. Churchill is at least $433.19 as of August 27th, 2024. Mr. Churchill owns 19,871 shares of Baudax Bio stock worth more than $433 as of December 16th. This net worth evaluation does not reflect any other investments that Mr. Churchill may own. Learn More about Winston J. Churchill's net worth.

How do I contact Winston J. Churchill?

The corporate mailing address for Mr. Churchill and other Baudax Bio executives is 490 LAPP ROAD, MALVERN PA, 19355. Baudax Bio can also be reached via phone at 484-395-2440 and via email at [email protected]. Learn More on Winston J. Churchill's contact information.

Has Winston J. Churchill been buying or selling shares of Baudax Bio?

Winston J. Churchill has not been actively trading shares of Baudax Bio during the last quarter. Most recently, on Tuesday, August 31st, Winston J. Churchill bought 2,500 shares of Baudax Bio stock. The stock was acquired at an average cost of $25.20 per share, with a total value of $63,000.00. Learn More on Winston J. Churchill's trading history.

Who are Baudax Bio's active insiders?

Baudax Bio's insider roster includes Arnold Baskies (Director), Richard Casten (CFO), Winston Churchill (Director), and Geraldine Henwood (CEO). Learn More on Baudax Bio's active insiders.

Winston J. Churchill Insider Trading History at Baudax Bio

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/31/2021Buy2,500$25.20$63,000.00View SEC Filing Icon  
See Full Table

Winston J. Churchill Buying and Selling Activity at Baudax Bio

This chart shows Winston J Churchill's buying and selling at Baudax Bio by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Baudax Bio Company Overview

Baudax Bio logo
Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care related settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with other non-NSAID analgesics. It also develops BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMB, which is in phase I clinical trial, as well as a proprietary blockade reversal agent; and BX3000, a NMB reversal agent that is in preclinical studies. Baudax Bio, Inc. was incorporated in 2019 and is based in Malvern, Pennsylvania.
Read More

Today's Range

Now: $0.02
Low: $0.02
High: $0.02

50 Day Range

MA: $0.02
Low: $0.02
High: $0.03

2 Week Range

Now: $0.02
Low: $0.01
High: $3.47

Volume

310,800 shs

Average Volume

281,029 shs

Market Capitalization

$1.14 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.57